Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cizdol-N
- Development stage
- Unknown
- Lead developer
- Maan Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Sublingual
01
Overview
Cizdol-N is a combination sublingual tablet manufactured by Maan Pharmaceuticals, containing buprenorphine and naloxone. It is indicated for the treatment of opioid dependence and de-addiction as part of medication-assisted treatment (MAT). Buprenorphine acts as a partial agonist at the mu-opioid receptor, which helps alleviate withdrawal symptoms and cravings without producing the intense euphoria associated with full opioid agonists. Naloxone, an opioid receptor antagonist, is included to deter misuse; it remains inactive when taken sublingually as directed but blocks opioid effects if the tablet is crushed and injected.
- Brand names
- Cizdol-N
- Other names
- Buprenorphine and Naloxone Sublingual Tablets I.P.Buprenorphine/Naloxone combination
02
Targets
DOR (Opioid Receptor Delta 1)MOR (Mu opioid receptor)KOR (Kappa opioid receptor)
Beyond the preview
Go deeper on Cizdol-N.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cizdol-N.